Utility scores and treatment preferences for clinical early-stage cervical cancer.

[1]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[2]  S. Kulasingam,et al.  Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. , 2009, Gynecologic oncology.

[3]  K. Kapp,et al.  Quality of life and sexual functioning after cervical cancer treatment: a long‐term follow‐up study , 2009, Psycho-oncology.

[4]  G. Scambia,et al.  Quality of life and psychological distress in locally advanced cervical cancer patients administered pre-operative chemoradiotherapy. , 2008, Gynecologic oncology.

[5]  S. Kulasingam,et al.  Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis. , 2007, Gynecologic oncology.

[6]  Steven J Frank,et al.  An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. , 2007, The Journal of urology.

[7]  S. Dewilde,et al.  Health state utilities for metastatic breast cancer , 2006, British Journal of Cancer.

[8]  Grazyna Adamiak,et al.  Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .

[9]  D. Bodurka,et al.  Quality of life and sexual functioning in cervical cancer survivors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Huh,et al.  Management strategies for stage IB2 cervical cancer: a cost-effectiveness analysis. , 2005, Gynecologic oncology.

[11]  J. Rader,et al.  Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? , 2004, Gynecologic oncology.

[12]  R. Bentley,et al.  Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. , 2004, Gynecologic Oncology.

[13]  Mitchell Morris,et al.  Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Bodurka,et al.  Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? , 2002, Gynecologic oncology.

[15]  F. Stehman,et al.  The abandoned radical hysterectomy: a Gynecologic Oncology Group Study. , 2000, Gynecologic oncology.

[16]  P. Grigsby,et al.  Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  N Urban,et al.  Quality of life in survivors of colorectal carcinoma , 2000, Cancer.

[18]  J. Brazier,et al.  A Review of the Use of Health Status Measures in Economic Evaluation , 1999, Journal of health services research & policy.

[19]  B N Bundy,et al.  Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B N Bundy,et al.  A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. , 1999, Gynecologic oncology.

[21]  B N Bundy,et al.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. , 1999, The New England journal of medicine.

[22]  B N Bundy,et al.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. , 1999, The New England journal of medicine.

[23]  D. Fishman,et al.  Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists. , 1998, Gynecologic oncology.

[24]  A. Oza,et al.  Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. , 1997, Gynecologic oncology.

[25]  F. Landoni,et al.  Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer , 1997, The Lancet.

[26]  C. McPherson,et al.  Quality of life and treatment outcomes , 1997, Cancer.

[27]  J. Wharton,et al.  The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. , 1994, International journal of radiation oncology, biology, physics.

[28]  C. Morrow,et al.  Relationship between surgical‐pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study , 1991, Gynecologic oncology.

[29]  G. Morley,et al.  Radical hysterectomy versus radiation therapy for stage ib squamous cell cancer of the cervix , 1991, Cancer.

[30]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[31]  M. Newton,et al.  Radical hysterectomy or radiotherapy for stage I cervical cancer. A prospective comparison with 5 and 10 years follow-up. , 1975, American journal of obstetrics and gynecology.

[32]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[33]  C. Sugar,et al.  Putting the 'Q' in quality adjusted life years (QALYs) for advanced ovarian cancer - An approach using data clustering methods and the internet. , 2007, European journal of cancer.

[34]  A. Hanlon,et al.  Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[35]  E. A. Nelson,et al.  Systematic reviews of wound care management: (2). Dressings and topical agents used in the healing of chronic wounds. , 1999, Health technology assessment.

[36]  P. Grigsby.  Primary radiotherapy for stage IB or IIA cervical cancer. , 1996, Journal of the National Cancer Institute. Monographs.

[37]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .